Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2003

View Archived Issues

New data on memantine in moderate to severe Alzheimer's disease

Intracellular fate of NB-1011 characterized by NewBiotics scientists

Optimization of farnesyltransferase inhibitors described at ACS by Pharmacopeia

RXR modulators as novel therapies for type 2 diabetes

Probiodrug presents DPP-I inhibitors for use in cancer and other diseases

New series of platelet ADP receptor inhibitors identified at Millennium

Antitumor duocarmycin analogues claimed by researchers at Scripps Research Institute

Euroceltique scientists prepare and test novel sodium channel blockers

New NPY Y5 receptor modulators in early development at AstraZeneca

Roche presents new CCR3 receptor antagonists and their use in asthma therapy

Data safety monitoring board recommends continuation of Fibrillex phase II/III trial

New Rapamune indication approved

StemCells granted patent for methods of isolating pancreatic progenitor cells

Affitech and NatImmune collaborate in colon cancer

Phase I IND amendment for Oxycyte submitted

Alizyme completes enrollment of phase IIb trial of renzapride

AG-858/Gleevec combination therapy subject of new phase II trial in CML

Tolvaptan shows no signs of drug interactions with warfarin or amiodarone

Efficacy results reported from pilot phase IIa study of DB-289 in pneumonia

FDA lifts clinical hold on trials of MacroChem's SEPA-based drugs

OSI updates Tarceva program progress

Pharmacokinetics and metabolism of bazedoxifene assessed in postmenopausal women

Orally active, nonemetogenic PDE4 inhibitor shows respiratory antiinflammatory activity

AWD-33-159: a structurally and mechanistically novel anticonvulsant

Macrocyclic thrombin inhibitors with high potency and selectivity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...